toripalimab
toripalimab: 22 clinical trials tracked.
toripalimab evidence translation
What we can confirm
22 tracked trials
What it means
What to watch
Prepared research question
What is verified about toripalimab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 9 study sponsors
Related indications
Clinical Trials (22)showing 10 most recent
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
Primary endpoint: Median Progression Free Survival
Master Protocol for A Phase 1b/2 Study of Neoadjuvant Immunotherapy in Microsatellite Stable (MSS) Colorectal Cancer (CRC) Subjects With Resectable Liver Metastases
Primary endpoint: Number of dose limiting toxicities (DLTs)
REMEDY-RCC: Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma - A Prospective, Exploratory, Single-Center Study
Primary endpoint: Objective Response Rate(ORR)
A Phase I/II Multicenter, Non-randomized, Open-label, Dose Escalation and Expansion Study of IPG7236 Combined With Toripalimab Treatment of Advanced Solid Tumors in Adult Patients to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity
Primary endpoint: Incidence of Dose-Limiting Toxicity (DLT)
A Phase II Window of Opportunity in Preserving Laryngeal Function (WOLF) Trial
Primary endpoint: 1-Year Disease-free survival (DFS)
A Phase 2 Study of Toripalimab in Combination With Cisplatin and Docetaxel (PDT) for Induction Therapy in CPS-Positive Locally Advanced Head and Neck Squamous Cell Carcinoma
Primary endpoint: Proportion Grade 3-5 TRAE-free during induction therapy
Neoadjuvant Chemotherapy and PD-1 Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
Primary endpoint: Major Pathological Response (MPR)
Phase II Exploratory Study of Toripalimab Combined With Stereotactic Body Radiation Therapy in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy
Primary endpoint: Pathologic complete response（pCR）
NECTAR Study: A Multicenter, Open-label, Randomized Phase II Study of Neoadjuvant Toripalimab Plus 9MW2821 Versus Upfront Radical Nephroureterectomy With/Without Lymph Node Dissection in Patients With Local Upper Tract Urothelial Carcinoma (UTUC)
Primary endpoint: Percentage of Participants With Pathologic Complete Response (pCR)
Phase II Trial of Neoadjuvant Toripalimab in Combination With Chemotherapy Followed by Transoral Robotic Surgery or Risk/Response Stratified Chemoradiotherapy for Locoregional HPV16+ Oropharyngeal Cancer: TARGET HPV Cohort 2
Primary endpoint: Deep Response Rate (DRR) with toripalimab + chemotherapy